COMMUNICATION

COM-2025-074

6 OCTOBER 2025

PLEASE REVIEW

Drug Information

PharmPix Clinical Department

PharmPix is committed to the health and wellness of our members.

The clinical team wants to communicate the latest up-to-date drug information requested.

Drug Information:

Remember that medical literature is dynamic and is continuously changing as new scientific knowledge is developed. We exhort the frequent revision of treatment guidelines to assure that your recommendations are consistent with the most updated information.

It is our priority to offer high-quality services and support practices for health promotion and diseases prevention. If you have any questions or wish to have more information regarding this document, you can call us directly or view PharmPix communications online.

QUESTIONS

Call us at 787-522-5252-ext.219

Access our recent communications at our providers' portal: https://www.pharmpix.com/providers/

Enbumyst™: The First Intranasal Diuretic

The FDA has approved Enbumyst for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including nephrotic syndrome in adults. This is a nasal spray formulation of bumetanide and the first self-administered nasal diuretic.

Bumetanide is a loop diuretic that is available as an oral tablet and injectable therapy (for intravenous or intramuscular administration).

When administering the medication, patients should alternate the spray between the right and left nostrils, and it should not be administered against the wall of the nose. Enbumyst is not intended for chronic use and is supplied in a unit-dose nasal spray containing bumetanide 0.5mg per 0.1mL. The recommended total daily dosage is 0.5 mg to 2 mg administered once daily.

Key Findings in the Clinical Trial

The approval of Enbumyst came from a clinical trial that compared the efficacy and absorption of intranasal bumetanide with the other formulations available: oral and intravenous (IV) bumetanide. Study participants received all 3 forms of the drug in a different order and were monitored for 10 days.

Results showed that the effect of the nasal formulation did not significantly vary from the other two formulations. A 2 mg dose of Enbumyst on diuresis, natriuresis, and potassium urine excretion over 0 to 8 hours and 0 to 24 hours was similar to that of a 2 mg bumetanide oral tablet and 2 mg bumetanide IV injection.

In terms of safety, the most common adverse reactions were hypovolemia, which occurred in 4.8% of patients, and headache, which was reported by 3% of patients.

If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252-ext.219. Our pharmacists will help you. In addition, know that you can access our recent communications at our providers' portal: https://www.pharmpix.com/providers/.

pharmpix
POWERED BY ONEARK

REFERENCES:

1. Gastroenterology Advisor. (2025, September 24). FDA approves Enbumyst, an intranasal formulation of bumetanide. *Gastroenterology Advisor*. https://www.gastroenterologyadvisor.com/news/fda-approves-enbumyst-an-intranasal-formulation-of-bumetanide/
2. Lutton, L. (2025, September 18). FDA approves first intranasal diuretic, Enbumyst. *Managed Healthcare Executive*. https://www.managedhealthcareexecutive.com/view/fda-approves-first-intranasal-diuretic-enbumyst
3. Cortasis Therapeutics. (2025). Enbumyst [package insert].

urac ACCREDITED Pharmacy Benefit Management Expires 12/01/2025

2 Street 1, Suite 500
Guaynabo, PR 00968

Tel. 787.522.5252
Fax 866.912.2830

www.pharmpix.com
FRM-CL-000130-001

CLINICAL PEARLS BY PHARMPIX